EL7.AI
StocksUpdated×2•Originally published 17 June 2026•Updated 18 June 2026•
1 min read

Legend Biotech Prices $226M Public Offering at $29.35 Per ADS

Key Facts

1Legend Biotech announced the commencement of an underwritten public offering of $225 million of American Depositary Shares (ADSs).
2The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold.
3Tianci International closed a $4.9 million public offering at a price of $0.81 per unit.

Moving forward with its capital expansion plans, Legend Biotech has formally priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 per share. The company expects to generate approximately $226 million in gross proceeds, with the closing of the offering scheduled for June 23, 2026. Additionally, underwriters have been granted a 30-day option to purchase up to an additional 1,155,000 ADSs under the same terms.

The pricing represents a strategic discount to recent trading levels, a common practice in the biotechnology sector to ensure full subscription for large-scale raises. For context, industry peer Tianci International recently closed a $4.9 million offering at $0.81 per unit, illustrating the sector's ongoing reliance on equity markets for clinical funding. Per market data, such discounted offerings typically induce immediate price adjustments as the market absorbs the new share supply.

LEGN shares were positioned at $33.38 (at close June 16, 2026), though the $29.35 offering price is expected to act as a primary anchor for near-term price action. Investors should look toward the official offering close on June 23, 2026, as a key milestone, while also monitoring the Michigan Consumer Sentiment report on June 12, 2026, for broader cues on growth-stock liquidity.